Overall Survival Results for Encorafenib Plus Binimetinib in BRAF-Mutant Melanoma
Keith T. Flaherty, MD, professor of Medicine, Harvard Medical School, director of Clinical Research, Massachusetts General Hospital, discusses overall survival results from the phase III COLUMBUS trial investigating encorafenib plus binimetinib versus vemurafenib (Zelboraf) or encorafenib in BRAF-mutant melanoma during the 2018 ASCO Annual Meeting.
Keith T. Flaherty, MD, professor of Medicine, Harvard Medical School, director of Clinical Research, Massachusetts General Hospital, discusses overall survival (OS) results from the phase III COLUMBUS trial investigating encorafenib plus binimetinib versus vemurafenib (Zelboraf) or encorafenib inBRAF-mutant melanoma during the 2018 ASCO Annual Meeting.
Earlier results showed the median progression-free survival rate for the combination of encorafenib and binimetinib was just under 15 months, which is a few months longer than what has been achieved with any other melanoma therapy that has recently emerged. Strikingly, the median OS was just over 33 months, which is also markedly longer than what has previously been seen. These results represent quite a striking milestone in this disease, Flaherty says.
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
